YARW · XBRL financial data

Yarrow Bioscience financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (YARW's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	20,993	14,755	477	424	501	570
Cost of goods and services sold	1,392	3,348	—	—	—	—
Research and development	43,533	24,958	18,385	16,307	30,946	19,237
Selling, general and administrative	89,543	54,481	16,387	—	—	—
General and administrative	—	—	16,387	13,375	13,192	11,082
Operating income (loss)	(252,546)	(68,032)	(34,295)	(29,258)	(43,637)	(29,749)
Interest expense	4,390	5,610	0	—	—	—
Other income (expense)	(1,110)	(135)	363	1,386	3,834	3,017
Income tax expense (benefit)	(258)	(448)	13	0	4	4
Net income (loss)	(255,568)	(73,329)	(23,210)	(28,452)	(39,834)	(26,483)
Earnings per share, basic‡ USD per share	141.73	25.54	(130.94)	(2.78)	(0.93)	(0.62)
Earnings per share, diluted‡ USD per share	141.73	25.54	(130.94)	(2.78)	(0.93)	(0.62)
Weighted average shares, basic‡ thousands of shares	1,802	2,862	177	10,273	42,589	42,768
Weighted average shares, diluted‡ thousands of shares	1,802	2,862	177	10,273	42,589	42,768

‡ Per-share figures and share counts are adjusted for the 1-for-17.98561151079137 stock split (February 2023); filings made before it reported them unadjusted.
† Share count changed about 1/17 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 78x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (YARW's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	57,563	42,250	30,908	30,620	19,926	24,027
Short-term investments	1,027	0	—	62,633	41,590	4,981
Marketable securities	1,027	0	0	62,633	41,590	4,981
Accounts receivable	15,819	7,583	173	—	—	—
Inventory	7,404	7,291	—	—	—	—
Prepaid and other current assets	4,591	5,119	2,127	2,656	2,921	1,002
Total current assets	87,259	63,186	38,275	95,963	64,437	30,010
Property and equipment, net	555	354	0	0	113	90
Right-of-use asset	1,583	0	0	207	93	0
Total assets	93,742	67,046	40,758	97,685	66,905	30,160
Accrued liabilities	11,452	8,593	4,381	4,119	9,272	941
Current portion of long-term debt	0	—	—	—	—	—
Total current liabilities	21,453	18,410	9,345	7,538	14,819	2,395
Long-term debt	33,174	0	—	—	—	—
Lease liability, non-current	853	0	0	99	0	—
Total liabilities	56,249	18,410	9,345	8,950	14,819	2,395
Accumulated deficit	(566,196)	(639,525)	(662,735)	(691,336)	(731,170)	(757,653)
Total stockholders' equity	37,493	48,636	31,202	88,735	52,086	27,765
Total liabilities and equity	93,742	67,046	40,758	97,685	66,905	30,160
Common shares outstanding (cover page)‡ thousands of shares	2,854	3,123	181	14,099	15,210	33,323

‡ Per-share figures and share counts are adjusted for the 1-for-17.98561151079137 stock split (February 2023); filings made before it reported them unadjusted.
† Share count changed about 1/17 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 78x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (YARW's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(255,568)	(73,329)	(23,210)	(28,452)	(39,834)	(26,483)
Stock-based compensation	18,100	8,080	4,297	3,305	3,303	2,308
Depreciation and amortization	341	109	72	0	4	23
Net cash from operating activities	(137,082)	(56,367)	(29,200)	(25,341)	(33,972)	(33,124)
Purchases of property and equipment	113	0	—	—	—	—
Net cash from investing activities	89,107	1,027	15,667	(57,354)	23,365	37,368
Proceeds from issuing common stock	61,639	75,981	1,470	—	—	—
Repayments of long-term debt	0	36,432	0	—	—	—
Net cash from financing activities	61,808	39,777	1,653	82,394	(141)	(143)
Net change in cash	—	—	—	(301)	(10,748)	4,101

† Share count changed about 1/17 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 78x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Insight Molecular Diagnostics	17,756	239	(9,268)*	32.7M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Kezar Life Sciences	66,229	not reported	(7,445)	7.4M	8.9 quarters	Q1 FY26 10-QMar 31, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Grace Therapeutics	13,756	not reported	(3,221)	21.0M	4.3 quarters	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.